Sorted By:

Relevance


Special Edition Fact Check Friday: Why disclosing negotiated discounts and rebates won’t help patients

PhRMA  |  Blog Post

The bottom line is private negotiations between PBMs and manufacturers drive our competitive marketplace and provide patients with access to a broad range of innovative medicines and foster the development of new treatments and cures patients desperately need.
http://catalyst.phrma.org/special-edition-fact-check-friday-why-disclosing-negotiated-discounts-and-rebates-wont-help-patients

Patients and Scientists Headline PhRMA’s “From Hope to Cures” Ad Campaign

PhRMA  |  Press Release

The campaign also features researchers like Janet who wake up every day trying to beat the odds and develop new treatments and cures for patients.
https://www.phrma.org/press-release/patients-and-scientists-headline-phrma-s-from-hope-to-cures-ad-campaign

PhRMA Statement on Secretary Burwell’s Delivery System and Payment Reform Announcement

PhRMA  |  Press Release

PhRMA’s Principles for Payment and Delivery System Reforms can be found here: http://www.phrma.org/phrma-principles-for-payment-and-delivery-system-reforms.
https://www.phrma.org/press-release/phrma-statement-on-secretary-burwell-s-delivery-system-and-payment-reform-announcement

100 Medicines and Vaccines in Development for HIV/AIDS

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.3 billion in 2009.
https://www.phrma.org/press-release/100-medicines-and-vaccines-in-development-for-hiv/aids

Clinical Trials Q&A : How does collaboration increase clinical trial awareness and access?

PhRMA  |  Blog Post

Lisa Hughes is the Director, Strategic Partnerships and Projects, National Patient Advocate Foundation and leads the Project Innovation and Cancer Innovation Coalition initiatives of the Patient Advocate Foundation and National Patient Advocate Foundation.
http://catalyst.phrma.org/clinical-trials-qa-how-does-collaboration-increase-clinical-trial-awareness-and-access

Combination of Vague Rules Defining a Patient and Lack of Enforcement Leads to Program Abuse

Chartpack  |  From Our Network

The lack of an appropriate patient definition means hospitals can profit from 340B discounts for patients whose prescriptions should not qualify for 340B....
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/combination-of-vague-rules-defining-a-patient-and-lack-of-enforcement-leads-to-program-abuse

Pilot Programs to Focus on Alzheimer’s Disease, Autoimmune Disorders and Type 2 Diabetes

PhRMA  |  Press Release

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.
https://www.phrma.org/press-release/pilot-programs-to-focus-on-alzheimer-s-disease-autoimmune-disorders-and-type-2-diabetes

Nearly 400 Medicines and Vaccines In Development to Fight Infectious Diseases

PhRMA  |  Press Release

Of the 395 medicines and vaccines in the current report, 24 are on a “fast track”-- a process designed to facilitate the development and expedite the review of drugs to treat serious diseases and fill a critical, unmet medical need.
https://www.phrma.org/press-release/nearly-400-medicines-and-vaccines-in-development-to-fight-infectious-diseases

Empowering consumers and improving access to out-of-pocket cost information

PhRMA  |  Blog Post

Coverage Classroom, as well as our glossary of key terms and other resources on AccessBetterCoverage.org.
http://catalyst.phrma.org/empowering-consumers-and-improving-access-to-out-of-pocket-cost-information

Medicare Monday: Provider consolidation drives up costs for patients and government

PhRMA  |  Blog Post

These analyses clearly show that proposals like the Part B “demonstration” are penny wise and pound foolish.
http://catalyst.phrma.org/medicare-monday-provider-consolidation-drives-up-costs-for-patients-and-government

Burden on Patients: Two Steps Forward and One Step Back for HIV/AIDS Patients

PhRMA  |  Blog Post

Instead, coverage under the Affordable Care Act is like taking two steps forward and one step back.
http://catalyst.phrma.org/burden-on-patients-two-steps-forward-and-one-step-back-for-hiv/aids-patients

Patient voices missing from media conversation about prescription drug abuse

PhRMA  |  Blog Post

PhRMA strongly supports these efforts as part of our extensive policy recommendations to combat opioid abuse, which you can find explained in-depth here.
http://catalyst.phrma.org/patient-voices-missing-from-media-conversation-about-prescription-drug-abuse

Disproportionate Share Hospitals Are Driving Current Volume and Future Program Growth

Chartpack  |  From Our Network

Disproportionate Share Hospitals drive 81% of 340B sales volume but only make up 9% of 340B entities....
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/disproportionate-share-hospitals-are-driving-current-volume-and-future-program-growth

Direct-to-Consumer Advertising Encourages Patient Engagement and Appropriate Use of Medicines

Chartpack  |  From Our Network

...
http://chartpack.phrma.org/2016-perspective/chapter-3/direct-to-consumer-advertising-encourages-patient-engagement-and-appropriate-use-of-medicines

Alzheimer's Disease and the Path Forward

PhRMA  |  Press Release

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.
https://www.phrma.org/press-release/alzheimer-s-disease-and-the-path-forward

Researching Alzheimer’s Medicines: Setbacks and Stepping Stones

PhRMA  |  Policy Paper

Biopharmaceutical researchers and the companies they work for are committed to finding treatments that realize the promise of our expanding scientific knowledge to halt or prevent the disease.
https://www.phrma.org/policy-paper/researching-alzheimer-s-medicines-setbacks-and-stepping-stones

Medicare Monday: More medicines in development for heart disease, stroke and other cardiovascular diseases

PhRMA  |  Blog Post

Food and Drug Administration (FDA).
http://catalyst.phrma.org/medicare-monday-more-medicines-in-development-for-heart-disease-stroke-and-other-cardiovascular-diseases

Researching Cancer Medicines: Setbacks and Stepping Stones

PhRMA  |  Report

While recent scientific advances have led to improved prevention, earlier diagnoses, and innovative treatments for many cancers, there is still tremendous unmet medical need.
https://www.phrma.org/report/researching-cancer-medicines-setbacks-and-stepping-stones

10 years of living and managing type 1 diabetes; lessons learned

PhRMA  |  Blog Post

Type 1 diabetes is a complex disease, but diabetes education and access to new technologies and treatments have been instrumental in my son being able to live a bold and healthy life.
http://catalyst.phrma.org/10-years-of-living-and-managing-type-1-diabetes-lessons-learned

Collaboration Is Key in Researching and Developing New Medicines

Chartpack  |  From Our Network

...
http://chartpack.phrma.org/2016-perspective/chapter-2/collaboration-is-key-in-researching-and-developing-new-medicines

U.S. Food and Drug Administration

From Hope To Cures  |  From Our Network

...
http://www.fromhopetocures.org/glossary

Beneficiaries Save Through Plan Competition and Manufacturer Negotiations

Chartpack  |  From Our Network

These savings are used to help reduce premiums, deductibles, and cost sharing.
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/beneficiaries-save-through-plan-competition-and-manufacturer-negotiations

Biomarkers and Surrogate Endpoints in Drug Development

From Hope To Cures  |  From Our Network

...
http://www.fromhopetocures.org/video/biomarkers-and-surrogate-endpoints-in-drug-development

Biopharmaceutical Companies Applaud New National Prevention and Health Promotion Strategy

PhRMA  |  Press Release

Industry-wide research and investment reached a record $67.4 billion in 2010.
https://www.phrma.org/press-release/biopharmaceutical-companies-applaud-new-national-prevention-and-health-promotion-strategy

Aly Rusciano: My Life with Juvenile Arthritis and step therapy

Access Better Coverage  |  From Our Network

Except I couldn’t take that medication, which meant my body made the antibodies, and that treatment stopped working.
http://www.accessbettercoverage.org/social-news/aly-rusciano-my-life-with-juvenile-arthritis-and-step-therapy

You have reviewed the first 250 results out of 2501. Each page contains 25 results. You're on page 10.

prev 7 8 9 10 11 12 next